The FDA testosterone warning that scared a generation of men away from treatment is gone. On 28 February 2025, the U.S. Food and Drug Administration told every manufacturer of testosterone products to strip the boxed warning about heart attacks and strokes from their labels, citing the results of the 5,246-man TRAVERSE trial. In the same breath, it added a new class-wide warning about raised blood pressure. So the honest summary is: the heart-attack fear didn’t hold up, but the label got more specific, not more relaxed.
We get asked about this at the clinic almost weekly. Men who read the 2015 headlines still arrive convinced that testosterone replacement therapy is a cardiac gamble. Here’s what the FDA testosterone warning change actually did, why it took a decade, and what the fine print means if you’re on treatment or thinking about it.
Where the FDA testosterone warning came from
Rewind to 2013 and 2014. Two observational studies suggested that men prescribed testosterone had more heart attacks and strokes than men who weren’t. Neither was a randomised trial, and both had well-documented flaws, but the signal was enough. In January 2014 the FDA announced it was investigating, and in March 2015 it ordered a boxed FDA testosterone warning (the agency’s most serious label alert) on every product in the United States.
The same 2015 action did something quieter that mattered just as much. It restricted the approved use of testosterone to men with low levels caused by a specific medical condition, such as testicular injury or a pituitary disorder, and told doctors not to prescribe it for the ordinary decline that comes with age. That “limitation of use” line is still on the label today.
Crucially, the FDA also demanded proof. It required the industry to fund a large, long-term safety trial. That trial became TRAVERSE.
What TRAVERSE found, in plain numbers
TRAVERSE enrolled 5,246 men aged 45 to 80 with low testosterone and either existing cardiovascular disease or a high risk of it. Half got a daily testosterone gel, half a placebo gel, and researchers followed them for an average of nearly three years. The results, published in the New England Journal of Medicine in 2023, showed major adverse cardiac events in 7.0% of the testosterone group and 7.3% of the placebo group. No difference.
That’s the headline the FDA acted on when it rewrote the testosterone warning. But TRAVERSE wasn’t a clean bill of health. The testosterone group had more atrial fibrillation (3.5% versus 2.4%), more acute kidney injury and more pulmonary embolism than placebo. Those are secondary findings and the absolute numbers are small, yet they are exactly the kind of detail that a good prescriber tracks. If you want the deeper discussion of risk versus benefit, our post on whether TRT is safe walks through it.
Three things the new FDA testosterone warning actually says
The February 2025 letter to manufacturers made three moves. First, it removed the boxed-warning language about increased cardiovascular risk from all testosterone products. Second, it required the TRAVERSE results to be added to every label so doctors can read the evidence themselves. Third, it kept the limitation-of-use statement for age-related hypogonadism unchanged.
And then came the part most news coverage skipped. Since 2018 the FDA had been requiring manufacturers to run ambulatory blood pressure monitoring (ABPM) studies, where patients wear a cuff that records readings around the clock. Those studies were now complete, and the agency said they “confirmed an increase in blood pressure with use of all testosterone products, class-wide.” So a new blood-pressure warning was added to every product that didn’t already carry one. You can read the full FDA statement on the agency’s site.
Why blood pressure is the testosterone warning to take seriously
The rise is modest, typically a few millimetres of mercury in systolic pressure, and it varies by formulation. Oral and some subcutaneous products showed it most clearly in premarket studies, which is why the FDA started asking questions back in 2016. But a small average shift across millions of men on long-term treatment adds up, and for someone already hovering at 138/88 it can be the difference between “watch it” and “medicate it.”
Testosterone raises blood pressure through a few overlapping routes: it increases red blood cell production, which thickens the blood, and it encourages sodium and water retention. We cover the first mechanism in detail in our piece on TRT and hematocrit, and the practical question of whether testosterone therapy causes high blood pressure gets its own post.
The takeaway from the blood-pressure side of the FDA testosterone warning is simple. A home blood-pressure cuff is now a standard piece of TRT kit, and a reading before every dose adjustment is as important as a testosterone level.
What the new FDA testosterone warning does not say
This is where marketing and medicine tend to part ways. The FDA did not declare testosterone safe for everyone, and it did not endorse prescribing it to healthy men whose levels have simply dipped with age. The limitation-of-use language survived precisely because TRAVERSE, for all its size, only studied men with confirmed hypogonadism and elevated cardiac risk, on a gel, for about three years. It says nothing about injections, pellets, ten-year use, or men under 45.
The revised FDA testosterone warning also didn’t touch the other monitoring that responsible clinics have always done. Prostate-specific antigen, hematocrit, lipids and estradiol still need checking, and our posts on TRT and prostate health and TRT and cholesterol explain why. The Endocrine Society guideline on testosterone therapy still recommends baseline and follow-up labs, and nothing in the 2025 label change alters that.
What this means if you’re considering treatment
For men with genuinely low testosterone and symptoms to match, the FDA testosterone warning saga ends on reassuring ground: the largest trial ever run found no excess of heart attacks or strokes. The catch is that the same trial and the same label update sharpened the focus on blood pressure, rhythm disturbances and kidney function, which means the quality of your monitoring matters more than ever, not less.
At Boost Health Clinic every TRT patient starts with a full hormone blood panel, a baseline blood-pressure reading and a frank conversation about which of these risks applies to them. If you’d like to know where you stand, book a consultation and we’ll go through your numbers together.